Literature DB >> 22311173

Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.

Junna Ye1, Yan Qi, Weiqing Wang, Fukang Sun, Qin Wei, Tingwei Su, Weiwei Zhou, Yiran Jiang, Wenqi Yuan, Jianfei Cai, Bin Cui, Guang Ning.   

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy accounting for approximately 0.02-0.2% of all cancer deaths. The molecular pathogenesis of ACC has been the hot topic of recent reviews but it is still poorly understood. It is imperative to have a better understanding on the pathophysiology of ACC so as to establish precise diagnosis and effective treatment. This study aims to identify the molecular markers between ACCs and adrenocortical adenomas (ACAs). With MLPA, we checked on 10 ACA and 9 ACC tissue samples. The MLPA results showed deletion on chromosomes 18q, 11q, 11p, and 13q and duplication on chromosomes 3q, 4q, 6p, and 19p. There was a significant difference in the number of aberration copies of the ataxia telangiectasia-mutated (ATM) gene located on chromosome 11q22-q23 between ACCs and ACAs. Five out of 9 (56%) ACC specimens had deletion of ATM (P = 0.011). RT-PCR result then demonstrated that ATM mRNA level is lower in ACCs than in ACAs (P < 0.001). In addition, immunohistochemistry (IHC) study of the 19 ACA and 18 ACC samples confirmed lower expression of ATM protein in ACCs than in ACAs (P < 0.001). The study demonstrated that ATM expression was diminished in ACC than in ACA, suggesting an important role of ATM in the tumorigenesis of ACC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22311173     DOI: 10.1007/s12020-012-9593-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

Review 1.  The many substrates and functions of ATM.

Authors:  M B Kastan; D S Lim
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

2.  Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

Authors:  Frans B L Hogervorst; Petra M Nederlof; Johan J P Gille; Cathal J McElgunn; Maartje Grippeling; Roelof Pruntel; Rein Regnerus; Tibor van Welsem; Resie van Spaendonk; Fred H Menko; Irma Kluijt; Charlotte Dommering; Senno Verhoef; Jan P Schouten; Laura J van't Veer; Gerard Pals
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 3.  The DNA damage response: ten years after.

Authors:  J Wade Harper; Stephen J Elledge
Journal:  Mol Cell       Date:  2007-12-14       Impact factor: 17.970

4.  Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications.

Authors:  M Dohna; M Reincke; A Mincheva; B Allolio; S Solinas-Toldo; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  2000-06       Impact factor: 5.006

Review 5.  Molecular genetics of adrenocortical tumours, from familial to sporadic diseases.

Authors:  Rossella Libé; Jérôme Bertherat
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

Review 6.  Adrenocortical carcinoma: clinical and laboratory observations.

Authors:  B L Wajchenberg; M A Albergaria Pereira; B B Medonca; A C Latronico; P Campos Carneiro; V A Alves; M C Zerbini; B Liberman; G Carlos Gomes; M A Kirschner
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

Review 7.  Hereditary breast cancer: from molecular pathology to tailored therapies.

Authors:  D S P Tan; C Marchiò; J S Reis-Filho
Journal:  J Clin Pathol       Date:  2008-08-04       Impact factor: 3.411

8.  DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture.

Authors:  Michael B Kastan
Journal:  Mol Cancer Res       Date:  2008-04       Impact factor: 5.852

9.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

10.  p53 mutations in sporadic adrenocortical tumors.

Authors:  H Ohgaki; P Kleihues; P U Heitz
Journal:  Int J Cancer       Date:  1993-05-28       Impact factor: 7.396

View more
  4 in total

Review 1.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

2.  Linking ATM Promoter Methylation to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM Territory.

Authors:  P Mehdipour; F Karami; Firouzeh Javan; M Mehrazin
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 3.  The role of microRNAs in the adrenocortical carcinomas.

Authors:  Xin Yu; Zheng Li
Journal:  Tumour Biol       Date:  2015-12-15

4.  A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation.

Authors:  Kai Kou; Haiwen Zhang; Conggui Zhang; Enbo Xie; Yuguo Chen; Guangyi Wang; Guoyue Lv
Journal:  World J Surg Oncol       Date:  2018-03-05       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.